Business · 01/04/2010
National Institutes of Health to Grant Exclusive Patent License for Cancer Vaccine Development to Bavarian Nordic Immunotherapeutics
The National Institutes of Health is considering granting an exclusive patent license to Bavarian Nordic Immunotherapeutics to develop cancer vaccines based on PANVAC and tumor-associated antigens, as outlined in several U.S. patents and patent applications.